首页 > 市场调查报告书 > 製药

处方药

市场调查报告书

商品编码

1535642

代谢紊乱治疗市场 - 按疾病、治疗、给药途径、最终用户、全球预测

Metabolic Disorder Therapeutics Market - By Disease, Therapy, Route of Administration, End-user, Global Forecast 2024-2032

出版日期: 2024年06月10日 | 出版商:

Global Market Insights Inc. | 英文 195 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在製药和生技公司为促进创新而对研发进行大量投资的带动下，代谢紊乱治疗市场规模在 2024 年至 2032 年间将实现 7.5% 的复合年增长率。举个例子，2023年11月，Biolexis Therapeutics, Inc.获得了1000万美元的资金，用于推进其代谢药物的开发。产业参与者和学术界之间不断加强的合作也为代谢紊乱治疗的新发现和进步铺平了道路。临床试验的增加正在扩大潜在治疗的管道，为患者提供新的选择，进一步塑造市场成长。

代谢紊乱治疗行业按疾病、治疗类型、给药途径、最终用户和地区进行分类。

就疾病而言，由于药物治疗、手术技术和改善患者预后的综合护理模式的进步，肥胖细分市场的市场规模可能在2024年至2032年录得强劲的复合年增长率。遗传和微生物组的新兴研究也正在影响未来的突破，使肥胖管理更加有效和个人化，从而促进该细分市场的成长。

对于最终用户来说，专科诊所领域的代谢紊乱治疗产业价值将在 2032 年之前扩大，因为他们越来越倾向于提供专业、全面和以患者为中心的护理。专科诊所正在积极实施代谢性疾病的创新疗法和治疗方法，例如使用新型药物、微创手术和先进的手术技术。这些诊所还提供慢性护理管理计划，以监测进度、根据需要调整治疗计划，并及时解决任何新出现的健康问题。

到2032年，亚太地区代谢紊乱治疗市场规模可能会出现显着的复合年增长率。等代谢紊乱的负担日益增加。不断涌现的政府措施和公共卫生运动在教育民众了解代谢紊乱方面也发挥着至关重要的作用，促进了区域产业的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 代谢紊乱的盛行率不断增加
  - 开发新疗法的研发活动不断增加
  - 提高认识和筛检计划
- 产业陷阱与挑战
  - 治疗费用高
  - 严格的监管要求
成长潜力分析
监管环境
技术景观
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按疾病分类，2021 - 2032 年

主要趋势
糖尿病
高胆固醇血症
溶小体贮积症
- 戈谢氏症
- 异染性脑白质营养不良
- 投手-谢伊
- 桑菲利波A
- 其他溶小体贮积症
肥胖
遗传性代谢紊乱

第 6 章：市场估计与预测：按治疗类型，2021 - 2032 年

主要趋势
药物治疗
酵素替代疗法
底物减少疗法
基因治疗
基于小分子的治疗
细胞移植

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

主要趋势
口服
注射用
其他给药途径

第 8 章：市场估计与预测：按最终用户划分，2021 - 2032 年

主要趋势
医院
专科诊所
其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

AbbVie, Inc.
Actelion Pharmaceuticals Ltd.
Amgen Inc.
AstraZeneca plc
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Eli Lilly and Company
Merck KGaA
Novo Nordisk A/S
Sanofi SA
Shire PLC

简介目录

Product Code: 9801

Metabolic Disorder Therapeutics Market size will record 7.5% CAGR between 2024 and 2032, led by significant investments in R&D by pharmaceutical and biotechnology companies to foster innovations. To cite an instance, in November 2023, Biolexis Therapeutics, Inc. secured $10 million in funding to advance its metabolic drug development. Rising collaborations between the industry players and academia are also making way for new discoveries and advancements in metabolic disorder therapeutics. The increase in clinical trials is expanding the pipeline of potential treatments for providing new options for patients, further shaping the market growth.

The metabolic disorder therapeutics industry is classified into disease, therapy type, route of administration, end-user, and region.

In terms of disease, the market size from the obesity segment may record a robust CAGR from 2024 to 2032 owing to the advances in pharmacotherapy, surgical techniques, and integrated care models for improving outcomes for patients. The emerging research in genetic and microbiome is also influencing future breakthroughs, making the management of obesity more effective and personalized, subsequently adding to the segment growth.

By end-user, the metabolic disorder therapeutics industry value from the specialty clinics segment will expand through 2032, due to their rising preference for offering specialized, comprehensive, and patient-centered care. Specialty clinics are actively implementing innovative therapies and treatments for metabolic disorders, such as the use of novel pharmacological agents, minimally invasive procedures, and advanced surgical techniques. These clinics also offer chronic care management programs to monitor progress, adjust treatment plans as needed, and address any emerging health issues promptly.

Asia Pacific metabolic disorder therapeutics market size may witness significant CAGR through 2032. This can mainly be ascribed to the increasing burden of metabolic disorders like diabetes, obesity, hyperlipidemia, and metabolic syndrome driven by changing lifestyles, dietary habits and the aging population. The surging government initiatives and public health campaigns are also playing a crucial role in educating the population about metabolic disorders, adding to the regional industry growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of metabolic disorders
  - 3.2.1.2 Rising R&D activities for developing novel therapeutics
  - 3.2.1.3 Growing awareness and screening programs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with treatment
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscap
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diabetes
5.3 Hypercholesterolemia
5.4 Lysosomal storage diseases
- 5.4.1 Gaucher's disease
- 5.4.2 Metachromatic leukodystrophy
- 5.4.3 Hurler - Scheie
- 5.4.4 Sanfilipo A
- 5.4.5 Other lysosomal storage diseases
5.5 Obesity
5.6 Inherited metabolic disorders

Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug therapy
6.3 Enzyme replacement therapy
6.4 Substrate reduction therapy
6.5 Gene therapy
6.6 Small molecule-based therapy
6.7 Cellular transplantation

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa